Lab Reference Library / FSH (Follicle-Stimulating Hormone) Hormones & Reproductive

FSH (Follicle-Stimulating Hormone)

FSH · Follicle-Stimulating Hormone · Follitropin

Reference range, optimal functional medicine levels, and why FSH is the pituitary signal driving follicle recruitment in women and sperm production in men, how elevated FSH reflects diminished ovarian reserve or primary testicular failure, and why cycle-day timing is critical for accurate FSH interpretation.

Pituitary GonadotropinOvarian Reserve

Women FM (Day 3)3 to 10 mIU/mL

DOR ThresholdAbove 10 mIU/mL

Menopause RangeAbove 40 mIU/mL

Men FM Optimal1.5 to 8 mIU/mL

← Back to Lab Reference Library

Category: Hormones & Reproductive | Also known as: FSH, Follicle-Stimulating Hormone, Follitropin

1. What This Test Measures

FSH (follicle-stimulating hormone) is a glycoprotein pituitary gonadotropin produced by specialized cells called gonadotrophs in the anterior pituitary gland. It is released in a pulsatile pattern regulated by gonadotropin-releasing hormone (GnRH) from the hypothalamus and modulated by negative feedback from gonadal hormones and peptides. In women, FSH is the primary signal driving ovarian follicle recruitment and development each menstrual cycle. In men, FSH acts on Sertoli cells in the seminiferous tubules to support spermatogenesis and sperm maturation.

In women, FSH levels are tightly coupled to ovarian status through a feedback loop: as follicles develop, they produce estradiol and inhibin B, which signal the pituitary to reduce FSH secretion. When the ovarian follicle pool diminishes (as occurs with aging toward menopause), estradiol and inhibin B feedback falls, and the pituitary increases FSH output in an attempt to recruit the remaining follicles. This compensatory FSH elevation is the central mechanism behind the rising FSH seen as women approach menopause, and it is the primary signal used clinically to assess ovarian reserve, the remaining functional egg supply.

In men, Sertoli cells produce inhibin B in response to FSH stimulation, providing the primary negative feedback that regulates testicular FSH drive. When testicular function is impaired (primary testicular failure), inhibin B falls, FSH rises, and the elevated FSH in the context of low testosterone and/or poor semen parameters indicates that the problem originates in the testes themselves rather than in the pituitary or hypothalamus.

2. Reference Range and Optimal Levels

Population and Context	Standard Reference	FM Optimal / Interpretation
Women, early follicular phase (Days 2 to 4)	3.5 to 12.5 mIU/mL	FM optimal below 8 mIU/mL; above 10 mIU/mL signals reduced ovarian reserve
Women, mid-cycle (LH surge phase)	4.7 to 21.5 mIU/mL	Peaks with LH surge; timing-specific interpretation required
Women, luteal phase	1.7 to 7.7 mIU/mL	Falls with progesterone feedback; not useful for ovarian reserve assessment
Perimenopause (variable)	3.0 to 50 mIU/mL	Rising trend over months to years signals perimenopausal transition
Postmenopause	25.8 to 134.8 mIU/mL	Typically above 40 mIU/mL; confirms cessation of ovarian follicular activity
Men (adult)	1.5 to 12.4 mIU/mL	FM optimal 1.5 to 8 mIU/mL; above 10 warrants evaluation for primary testicular failure
Premature ovarian insufficiency	Above 40 mIU/mL below age 40	With amenorrhea greater than 12 months; diagnosis requires two values 4 weeks apart

FSH is only interpretable for ovarian reserve assessment when drawn on cycle days 2, 3, or 4 (early follicular phase). FSH drawn at any other cycle phase reflects the dynamic hormonal changes of the cycle rather than basal pituitary drive. Concurrent early follicular phase estradiol should always be checked alongside FSH: if estradiol exceeds 80 pg/mL on the day of the FSH draw, the result may be artificially suppressed and requires repeat testing at a lower estradiol time point.

3. FSH and Ovarian Reserve Assessment

Day 3 FSH is the foundational ovarian reserve marker and the reference measurement against which newer markers like AMH and antral follicle count are contextualized, not replaced.

The ovarian reserve framework operates on a simple physiological principle: as the pool of remaining primordial follicles declines with age, the granulosa cells of recruited follicles produce progressively less inhibin B and estradiol per cycle, reducing the negative feedback that keeps FSH suppressed. The pituitary responds by increasing FSH output to try to recruit adequate follicular development. Rising basal FSH is therefore a direct readout of diminishing ovarian feedback capacity. In fertility medicine, a day 3 FSH above 10 mIU/mL is the threshold for concern in a woman actively trying to conceive; above 15 mIU/mL predicts poor response to ovarian stimulation; and above 20 mIU/mL in a woman below 40 warrants evaluation for premature ovarian insufficiency. In functional medicine (including longevity and hormone optimization practice where fertility may not be the primary concern), rising FSH also signals the beginning of the perimenopausal hormonal transition and the window for preventive intervention before estrogen deficiency drives bone loss, cardiovascular risk, cognitive changes, and genitourinary atrophy.

4. FSH in Men: Primary vs Secondary Hypogonadism

Elevated FSH: Primary Testicular Failure

Mechanism: when the testes cannot produce adequate testosterone and/or sperm, inhibin B falls and the pituitary increases FSH and LH output in compensation; elevated FSH in the context of low testosterone identifies the problem as originating in the testes (primary hypogonadism) rather than the pituitary or hypothalamus
Klinefelter syndrome (47,XXY): the most common cause of primary hypogonadism in men; typically presents with markedly elevated FSH (often above 20 mIU/mL), very low or absent sperm production, and low to low-normal testosterone; small firm testes; testosterone therapy is required but does not restore fertility without specialist intervention
Chemotherapy and radiation damage: gonadotoxic treatments elevate FSH from Sertoli cell damage even when testosterone production from Leydig cells partially recovers; FSH elevation in a cancer survivor indicates that spermatogenesis was more severely affected than steroidogenesis
Post-orchitis or varicocele: testicular inflammation from mumps orchitis, trauma, or bilateral varicocele can produce elevated FSH with impaired spermatogenesis; unilateral damage typically does not elevate FSH
Testicular sperm extraction (TESE) prediction: FSH level predicts but does not definitively determine TESE success; some men with markedly elevated FSH still have focal spermatogenesis that can be retrieved; microsurgical TESE outcome data show meaningful success even with FSH above 30 mIU/mL in motivated couples

Low or Normal FSH: Secondary (Central) Hypogonadism

Mechanism: when low testosterone is accompanied by low or inappropriately normal FSH (and LH), the problem is in the pituitary or hypothalamus, not the testes; the pituitary is not producing adequate gonadotropin drive to stimulate the testes; this pattern is called secondary or hypogonadotropic hypogonadism
Causes of secondary hypogonadism in men: obesity and insulin resistance (the most common cause in functional medicine practice); chronic exogenous testosterone or anabolic steroid use (which suppresses the hypothalamic-pituitary axis); hyperprolactinemia from a pituitary prolactinoma; Kallmann syndrome (congenital GnRH deficiency with anosmia); pituitary tumors, infiltrative disease, or radiation damage; chronic opioid use; severe illness or malnutrition
Clinical significance for TRT decision-making: in secondary hypogonadism from obesity or insulin resistance, addressing the root cause can restore axis function without TRT; in a young man with secondary hypogonadism who wants to preserve fertility, clomiphene citrate or human chorionic gonadotropin (hCG) stimulates the axis from the pituitary level and can raise testosterone while maintaining spermatogenesis, unlike exogenous testosterone which suppresses it
FSH in men on TRT: exogenous testosterone suppresses LH and FSH through negative feedback; FSH below 1 mIU/mL during TRT is expected and confirms adequate pituitary suppression; failure to suppress FSH despite testosterone therapy suggests non-compliance or inadequate absorption rather than primary testicular failure

5. FSH and the Perimenopausal Transition

Early perimenopause signal: the first reliable laboratory signal of perimenopausal transition is rising day 3 FSH above 10 mIU/mL in a woman with still-regular menstrual cycles; this may precede menstrual irregularity by years and provides an early window for preventive hormonal and skeletal interventions before estrogen deficiency produces irreversible consequences
FSH variability in perimenopause: FSH fluctuates significantly month to month during perimenopause, sometimes returning to apparently normal values before rising again; a single elevated FSH measurement in a symptomatic perimenopausal woman should not be discounted because a subsequent measurement is normal; trend over time matters more than any single value
FSH as a monitoring tool during HRT: in women on estrogen therapy, FSH is suppressed by the administered estrogen feedback; FSH on HRT is not a useful ovarian reserve marker; it is sometimes used to assess adequacy of estrogen replacement, where FSH persistently above 30 to 40 mIU/mL on HRT may indicate insufficient estrogen dose to provide adequate endocrine feedback
Bone density intervention timing: accelerated bone loss begins approximately 2 years before the final menstrual period when estrogen decline steepens; rising FSH (particularly above 15 to 20 mIU/mL) during perimenopause identifies the window for bone density baseline measurement (DXA scan) and preventive intervention before significant loss accumulates

6. Supporting Healthy FSH Regulation

In Women: Ovarian Support

DHEA supplementation (25 to 75mg daily): evidence from fertility medicine shows that DHEA supplementation over 3 to 6 months modestly improves ovarian response in women with diminished ovarian reserve; the mechanism involves DHEA conversion to androgens that support early follicular development through androgen receptor signaling in granulosa cells; FSH may modestly fall as ovarian response improves; most evidence is in women undergoing IVF
CoQ10 as ubiquinol (400 to 600mg daily): mitochondrial energy support in oocytes and granulosa cells; evidence that ubiquinol improves ovarian response and egg quality in women with DOR; CoQ10 declines with age in oocyte mitochondria, and deficiency may contribute to the reduced follicular responsiveness that drives FSH elevation
Optimal vitamin D (60 to 80 ng/mL): vitamin D receptor (VDR) signaling in granulosa cells supports follicular development and AMH production; deficiency is associated with poorer ovarian reserve markers and reduced fertility outcomes; supplementation to optimal range is a low-risk, high-value intervention
Melatonin (3mg at bedtime, beginning 6 weeks before IVF retrieval): antioxidant protection for oocytes in follicular fluid; reduces oxidative damage to developing follicles; used as adjunct in women with DOR in assisted reproduction; not a standalone FSH-lowering intervention
Stress management and HPA axis support: chronic cortisol elevation suppresses GnRH pulsatility and can impair follicular development; addressing psychological and physiological stress supports hypothalamic-pituitary-ovarian axis function

In Men: Testicular Support

Address obesity and insulin resistance: the most common and reversible cause of secondary hypogonadism (low FSH with low testosterone) in men is obesity-driven hypothalamic-pituitary suppression from leptin resistance, hyperestrogenism from adipose aromatase, and metabolic dysfunction; weight loss of 10 to 15% often partially restores the HPG axis in obese men without requiring TRT
Clomiphene citrate (25 to 50mg every other day or daily): estrogen receptor antagonist that blocks hypothalamic negative feedback from estrogen, increasing GnRH and therefore LH and FSH secretion; used in men with secondary hypogonadism who want to raise testosterone while maintaining fertility; raises both testosterone and FSH/LH simultaneously; not appropriate in primary testicular failure (high FSH) where the testes cannot respond
Zinc (15 to 30mg daily): zinc is required for LH receptor sensitivity on Leydig cells and FSH receptor expression on Sertoli cells; zinc deficiency impairs both testosterone production and spermatogenesis; serum zinc target 80 to 110 mcg/dL
Avoid testicular heat exposure: scrotal temperature elevation from sedentary work, tight clothing, or hot tub use impairs spermatogenesis by Sertoli cells; FSH rises compensatorily; behavioral modifications to maintain scrotal temperature below core body temperature improve Sertoli cell function

Monitoring and Context

Always pair with LH: FSH interpreted without concurrent LH misses critical information; elevated FSH with elevated LH confirms primary gonadal failure; elevated FSH with low or normal LH is an unusual pattern requiring evaluation for selective pituitary dysfunction; normal FSH with elevated LH may indicate luteal phase defect or early ovarian compromise
Always pair with estradiol in women: day 3 estradiol above 80 pg/mL suppresses FSH and can produce a falsely reassuring low FSH result; always check estradiol simultaneously with day 3 FSH to confirm the result is valid; some practitioners consider a day 3 estradiol above 60 pg/mL sufficient to invalidate the FSH for ovarian reserve interpretation
Complement with AMH: FSH reflects current pituitary drive; AMH reflects the size of the remaining follicle pool; together they provide a more complete ovarian reserve picture; AMH falls before FSH rises in most women, making AMH the earlier marker of declining reserve
Antral follicle count (AFC): transvaginal ultrasound count of antral follicles visible at days 2 to 5 of the cycle; the most direct assessment of available follicle pool; correlates closely with AMH and provides the information that neither FSH nor AMH can: actual follicle number in the current cycle
Serial tracking: a single FSH measurement is less informative than the trend over 3 to 6 months; rising FSH confirms declining reserve; stable FSH (even if mildly elevated) provides some reassurance of stable reserve; compare on the same cycle day each time for meaningful trend analysis

7. Related Lab Tests

LHCompanion Pituitary Gonadotropin; Always Measured Alongside FSH

→

AMHEarlier and More Consistent Ovarian Reserve Marker; Complements FSH

→

EstradiolMust Be Checked Simultaneously With Day 3 FSH to Validate the Result

→

ProlactinHyperprolactinemia Suppresses GnRH and Impairs FSH Release; Check When FSH Is Low

→

TestosteroneCompanion Measurement in Male Hypogonadism; FSH Pattern Distinguishes Primary from Secondary

→

DHEA-SAdrenal Androgen Support for Ovarian Reserve; Complement to FSH in DOR Evaluation

→

8. Clinical Perspective

Clinical Perspective

FSH is the laboratory confirmation of a conversation many women are not having early enough with their physicians. When a 38-year-old woman comes in with regular cycles, no fertility concerns, and an FSH of 13 mIU/mL, the clinical question is not just what her fertility outlook is; it is what her hormonal trajectory means for her bone density, cardiovascular health, cognitive function, and quality of life over the next 10 to 15 years as estrogen declines. Rising FSH in a woman in her late 30s or early 40s with no fertility concerns is still clinically significant because it marks the beginning of the perimenopausal hormonal transition, and the decisions made in that window about lifestyle, bone health monitoring, preventive supplementation, and readiness for hormone therapy have a decade-long impact on how she will experience menopause and post-menopause. In men, FSH is the single measurement that tells me immediately whether low testosterone is a testicular problem or a central axis problem, and that distinction completely changes the treatment approach. One patient gets TRT; the other gets clomiphene, weight management, and a conversation about why his hypothalamus stopped signaling adequately. FSH does not answer every question, but it always changes the clinical direction.

Brian Lamkin, DO | Founder, The Lamkin Clinic | Edmond, Oklahoma

9. Frequently Asked Questions

What does an elevated FSH level indicate?

Elevated FSH, defined functionally as above 10 mIU/mL in premenopausal women in the early follicular phase, indicates that the pituitary is working harder than normal to stimulate follicular development, signaling reduced ovarian response. This pattern is called diminished ovarian reserve (DOR) and means fewer and/or lower-quality follicles remain available for recruitment. In women above 40, FSH above 10 mIU/mL is common and expected as menopause approaches. In women below 35, FSH above 10 mIU/mL warrants urgent fertility evaluation. FSH above 40 mIU/mL in a woman below 40 years old with cessation of menses for more than 12 months meets criteria for premature ovarian insufficiency (POI).

On what day of the cycle should FSH be measured?

FSH must be drawn on cycle days 2, 3, or 4 (the early follicular phase) to be interpretable for ovarian reserve assessment. FSH drawn at any other cycle phase reflects the dynamic FSH changes of the cycle rather than the basal pituitary set point that indicates ovarian reserve. Women without regular cycles should have FSH checked alongside estradiol; if estradiol is above 80 pg/mL at the time of the FSH draw, the estrogen-mediated FSH suppression may produce a falsely low FSH that underestimates ovarian reserve depletion. Retesting at a time when estradiol is below 50 pg/mL is required for accurate basal FSH interpretation.

What is the relationship between FSH and AMH for ovarian reserve?

FSH and AMH (anti-Mullerian hormone) measure ovarian reserve from different directions. FSH measures pituitary demand: it rises when the ovary is less responsive, reflecting the hypothalamic-pituitary system compensating for reduced follicular feedback. AMH measures ovarian supply: it is produced directly by granulosa cells of antral follicles and falls as follicle pool size decreases. AMH has several advantages over FSH for ovarian reserve assessment: it can be drawn on any cycle day, it is more consistent month-to-month, and it begins to fall earlier in the trajectory of ovarian aging before FSH rises significantly. Together, FSH and AMH provide complementary information; a patient with normal FSH but low AMH has meaningful ovarian reserve reduction that FSH alone would miss.

Can FSH be elevated in men and what does it indicate?

Yes. In men, FSH from the pituitary stimulates Sertoli cells in the testes to support sperm production. Elevated FSH in men (above 10 to 12 mIU/mL depending on the laboratory) indicates primary testicular failure: the testes are not producing adequate feedback inhibin B, so the pituitary increases FSH drive in an attempt to compensate. Common causes include Klinefelter syndrome (XXY), history of chemotherapy or radiation to the testes, varicocele, cryptorchidism, and autoimmune orchitis. Elevated FSH in men with azoospermia or severe oligospermia on semen analysis signals that testicular sperm extraction may be the only path to biological paternity. Normal or low FSH in men with low testosterone and poor semen parameters points toward secondary (central) hypogonadism rather than primary testicular failure.

How does FSH change during perimenopause and menopause?

FSH rises progressively through perimenopause as the declining ovarian follicle pool reduces inhibin B and estradiol feedback on the pituitary. In early perimenopause, FSH may be variably elevated (12 to 25 mIU/mL) with maintained menstrual cycles. In late perimenopause, FSH rises more consistently (20 to 40 mIU/mL) as cycles become irregular. After menopause, defined as 12 consecutive months without menstruation, FSH typically exceeds 40 mIU/mL and may reach 100 to 150 mIU/mL as the pituitary continues releasing high FSH without any ovarian follicular response. This persistently elevated FSH is the biochemical confirmation of menopause. However, FSH alone should not be used as the sole diagnostic criterion for menopause; it must be interpreted alongside LH, estradiol, and clinical history.

Content authored and clinically reviewed by Brian Lamkin, DO, founder of The Lamkin Clinic in Edmond, Oklahoma. Brian Lamkin, DO has 25+ years of experience in functional and regenerative medicine. This page reflects current functional medicine practice standards and is updated as new clinical evidence becomes available.

Rising FSH identifies declining ovarian reserve in women and primary testicular failure in men. Cycle-day timing and concurrent estradiol measurement are essential for accurate interpretation.

FSH is a core component of every comprehensive hormone evaluation at The Lamkin Clinic. Schedule a consultation for a complete reproductive hormone assessment and personalized hormone optimization plan.

Schedule a Consultation

Medical Disclaimer: This content is provided for educational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Lab interpretation should always be performed in clinical context by a qualified healthcare provider. Reference ranges and optimal targets may vary based on individual patient history, clinical presentation, and laboratory methodology. Schedule a consultation to discuss your specific results with Dr. Lamkin.